J. Canon

发表

Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery

J. Machiels, B. Tombal, P. Forget, 2013, Annals of Surgical Oncology.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

C. Gridelli, S. Thongprasert, E. Felip, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2013, The New England journal of medicine.

Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer

J. Machiels, J. Canon, S. Oudard, 2012, Cancer Chemotherapy and Pharmacology.

Effect of lithium on diffusion chamber granulopoiesis.

J. Canon, G. Cornu, J. Ninane, 1984, International journal of cell cloning.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Marc Peeters, Bart Neyns, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families

J. Machiels, R. Helaers, M. Vikkula, 2020, Breast Cancer Research.

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer

C. Sempoux, J. Machiels, K. Haustermans, 2015, Targeted Oncology.

Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients

T Guillaume, I McNiece, S Miltenyi, 2000, Bone Marrow Transplantation.

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

T. Delozier, J. Bonneterre, B. Asselain, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flexible care in breast cancer.

M. Piccart, J. Canon, A. Wardley, 2021, ESMO open.

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

V. Georgoulias, E. Van Cutsem, J. Canon, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies

E. Van Cutsem, J. Canon, M. Opyrchal, 2019, BioDrugs.

Celyad's novel CAR T-cell therapy for solid malignancies.

J. Machiels, J. Canon, K. Odunsi, 2018, Current Research in Translational Medicine.

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

J. Canon, R. Pirker, J. Vansteenkiste, 2005, Investigational new drugs.

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

M. Berlière, J. Canon, A. van Maanen, 2021, BMC Cancer.

Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?

C. Sempoux, J. Machiels, J. Canon, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.

C. Sempoux, J. Machiels, V. Remouchamps, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

J. Hecht, G. Fasola, J. Canon, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

J. Hecht, G. Fasola, J. Canon, 2017, International Journal of Colorectal Disease.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials

J. Canon, M. Peeters, G. Pentheroudakis, 2018, British Journal of Cancer.

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

J. Tabernero, J. Canon, G. Bodoky, 2016, ESMO Open.

High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008)

H. Wildiers, J. Canon, Y. Beguin, 2010, Supportive Care in Cancer.

Cancer and renal insufficiency results of the BIRMA study

J. Machiels, H. Wildiers, J. Canon, 2010, British Journal of Cancer.

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

R. Paridaens, H. Wildiers, J. Canon, 2010, Breast Cancer Research and Treatment.

The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer

J. Canon, P. Delrée, Ahmad Merhi, 2017, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Gefitinib monotherapy in advanced non-small cell lung cancer (NSCLC): Experience from a large, Western community implementation study

K. Nackaerts, J. Canon, J. Vansteenkiste, 2006 .

Agrobacterium radiobacter bacteremia in oncologic and geriatric patients: presentation of two cases and review of the literature.

J. Canon, M. André, C. Lonchay, 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild‑type (WT) KRAS metastatic colorectal cancer (mCRC).

G. Fasola, J. Canon, F. Rivera, 2013 .

Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).

G. Fasola, J. Canon, F. Rivera, 2013 .

Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study.

T. Petit, J. Canon, D. Belpomme, 2003, Gynecologic oncology.

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3

N. Cascinelli, J. Naeyaert, J. Canon, 1995, International journal of cancer.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial

C. Bokemeyer, P. Gascón, J. Canon, 2012, Medical Oncology.

BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer

Y. Gillerot, J. Canon, A. Vindevoghel, 1998, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.

P. Neven, C. Desmedt, M. Piccart, 2022, Future oncology.

LBA9Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study

A. Vincent-Salomon, J. Lemonnier, J. Canon, 2017 .

Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

L. Mauriac, J. Canon, G. Romieu, 2009 .

Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.

M. Buyse, P. de Keyser, J. Canon, 1995, Anti-cancer drugs.

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

P. Pauwels, J. Canon, S. Tejpar, 2022, ESMO Open.

Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy

J. Canon, G. Bodoky, J. Vansteenkiste, 2005 .

Correction/Maintenance Dosing (Front Loading) of Darbepoetin alfa: Final Results from a Randomized Phase 3 Active Controlled Trial.

Lisa Anne Hendricks, J. Miguel, J. Canon, 2004 .

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS.

A. Vincent-Salomon, I. Bièche, F. Clatot, 2022, Analytical chemistry.

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

D. Miles, D. Cameron, J. Canon, 2017, European journal of cancer.

Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clinique de l'Université Catholique de Louvain, Br

J. Canon, H. van de Velde, Y. Humblet, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST.

J. Hecht, G. Fasola, J. Canon, 2015 .

Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment.

J. Canon, M. Peeters, T. Price, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized controlled trial of panitumumab in patients with metastatic colorectal cancer: subset analyses in elderly patients and in patients with poor performance status.

B. Neyns, J. Canon, Y. Humblet, 2007 .

PD-014First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

I. Bièche, F. Clatot, F. André, 2022, The Lancet. Oncology.

Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.

J. Canon, Y. Humblet, V. D’Hondt, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.

J. Canon, Y. Humblet, A. Feyens, 1989, Cancer research.

The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed.

J. Canon, Y. Humblet, M. André, 1999, Leukemia & lymphoma.

Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC).

J. Tabernero, J. Canon, G. Bodoky, 2015 .

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.

Stefano Iacobelli, Francis Lévi, Antoine Adenis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of irinotecan + 5FU/FA for patients with previously treated advanced gastric cancer.

E. Van Cutsem, J. Canon, F. Baert, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resistance to cisplatin: how to deal with the problem?

J. Canon, Y. Humblet, M. Symann, 1990, European journal of cancer.

Detection of small cell lung cancer bone marrow metastases by immunofluorescence.

J. Canon, Y. Humblet, H. Bazin, 1988, Pathologie-biologie.

Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

H. Wildiers, J. Canon, F. Bidard, 2020 .

Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.

J. Canon, G. Jerusalem, C. Focan, 2005, Anticancer research.

SACCHAROMYCES CEREVISIAE FUNGEMIA IN A HEAD AND NECK CANCER PATIENT: A CASE REPORT AND REVIEW OF THE LITERATURE

J. Canon, M. André, L. D'Hondt, 2004, Acta clinica Belgica.

Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

C. Sempoux, J. Machiels, K. Haustermans, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.

T. Delozier, M. Campone, T. Petit, 2009 .

Fatal Candida famata peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis who was treated with fluconazole.

J. Canon, G. Quindós, J. Pontón, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clostridium tertium bacteremia: contamination or true pathogen? A report of two cases and a review of the literature.

J. Canon, M. André, C. Lonchay, 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

J. Canon, J. Vansteenkiste, P. Vuylsteke, 2015, Lung cancer.

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

M. Beckmann, P. Fasching, P. Neven, 2012, Breast Cancer Research and Treatment.

MiR-210 Is Overexpressed in Tumor-infiltrating Plasma Cells in Triple-negative Breast Cancer

J. Canon, P. Delrée, Ahmad Merhi, 2019, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

J. Machiels, J. Canon, B. Sautois, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)

Mano, E. Perez, H. Gómez, 2013 .

Biology of small cell lung cancer: an overview.

J. Canon, Y. Humblet, M. Symann, 1990, The European respiratory journal.

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.

J. Machiels, I. Tinhofer, J. Canon, 2021, European journal of cancer.

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

C. Sempoux, J. Machiels, K. Haustermans, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report

J. Canon, F. Duhoux, I. Sinapi, 2016, Journal of Medical Case Reports.

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

J. V. van Meerbeeck, J. Canon, Y. Humblet, 2016, PloS one.

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.

J. Lemonnier, M. Campone, J. Canon, 2019, European journal of cancer.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

J. Machiels, F. Penault-Llorca, B. Asselain, 2012, The oncologist.

A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer.

J. Machiels, J. Canon, S. Oudard, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

M. Hidalgo, E. Van Cutsem, E. Raymond, 2018, International journal of cancer.

Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

J. Machiels, M. Lacroix-Triki, M. Campone, 2014, Breast Cancer Research.

Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies

S. Michiels, F. André, J. Lemonnier, 2019, Breast Cancer Research and Treatment.

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

I. Bièche, F. Clatot, F. André, 2022, BMJ Open.

Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies

J. Canon, Y. Humblet, M. André, 2003, Transfusion.

A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia*

J. Canon, M. Hedenus, D. Kotasek, 2007, Current medical research and opinion.

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications

J. Lemonnier, M. Campone, J. Canon, 2019, Breast Cancer Research.

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

A. Vincent-Salomon, J. Lemonnier, J. Canon, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

J. Machiels, L. Dirix, J. Canon, 2019, Annals of Oncology.

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

J. Lemonnier, M. Campone, D. Cameron, 2021 .

Silencing of casein kinase 1 delta reduces migration and metastasis of triple negative breast cancer cells

J. Canon, S. Laurent, P. Delrée, 2018, Oncotarget.

Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer

C. Sotiriou, D. Larsimont, M. Buyse, 2013, PloS one.

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

F. Penault-Llorca, J. Lemonnier, J. Canon, 2013, Breast Cancer Research and Treatment.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

J. Machiels, T. Delozier, F. Penault-Llorca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.

J. Canon, P. Fumoleau, Anne-Laure Martin, 2013, Bulletin du cancer.

TRIAL A phase I / II trial of the safety and clinical activity of a HER 2-protein based immunotherapeutic for treating women with HER 2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016 .

Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.

M. Buyse, P. de Keyser, J. Canon, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study

M. Nicolson, J. Canon, P. Schőffski, 2012, British Journal of Cancer.

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

J. Canon, G. Bodoky, J. Vansteenkiste, 2006, Journal of the National Cancer Institute.

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

J. Jassem, J. Canon, J. Douillard, 2010 .

BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer

M. Buyse, J. Mackey, J. Canon, 2007 .

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

H. Wildiers, J. Lemonnier, M. Lacroix-Triki, 2018, European journal of cancer.

Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963

T. Gorlia, F. Lévi, J. Canon, 2005 .

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).

C. Sotiriou, D. Larsimont, M. Piccart, 2007, European journal of cancer.

Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results.

T. Delozier, B. Asselain, J. Canon, 2006, Journal of Clinical Oncology.

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

W. Scheithauer, E. Van Cutsem, B. Neyns, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Ef ﬁ cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

J. Jassem, J. Canon, Y. Humblet, 2014 .

Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study

K. Nackaerts, J. Canon, J. Vansteenkiste, 2006, European Respiratory Journal.

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials

J. Lemonnier, M. Lacroix-Triki, M. Campone, 2023, Breast Cancer Research and Treatment.

260 A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: the RadiOxCape study

C. Sempoux, J. Machiels, P. Scalliet, 2003 .

Thrombo-Embolic Events in Cancer Patients with Impaired Renal Function

J. Canon, A. Awada, J. Baurain, 2014 .

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014 .

High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update.

J. Canon, C. Focan, M. Beauduin, 2004, Clinical breast cancer.

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

I. Bièche, F. Clatot, F. André, 2022, Cancer Research.

A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data

I. Vergote, J. Canon, Y. Humblet, 2005 .

Abstract OT1-18-02: First-line chemo-immunotherapy with durvalumab, paclitaxel and carboplatin with or without anti-CD73 antibody oleclumab in advanced or metastatic triple-negative breast cancer: Preliminary results of the randomized phase II SYNERGY trial

M. Piccart, F. Clatot, L. Buisseret, 2022, Cancer Research.

Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.

W. Guo, M. Hidalgo, J. Canon, 2015 .

Ovarian cancer associated with carcinomatous meningitis: a case report and review of the literature

J. Canon, M. André, P. Delrée, 2006, International Journal of Gynecologic Cancer.

Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer.

D. Amadori, J. Machiels, F. Cardoso, 2009 .

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

F. Penault-Llorca, F. André, J. Lemonnier, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.

H. Wildiers, D. Richel, J. Canon, 2012, Annals of Oncology.

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer

R. Neuwirth, J. Canon, K. Galinsky, 2021, Clinical Cancer Research.

Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.

J. Canon, C. Focan, M. Beauduin, 2000, Anticancer research.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.

J. Canon, J. Vansteenkiste, Yali Fu, 2013 .

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.

D. Amadori, J. Machiels, F. Cardoso, 2012, Breast.

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone

C. Sempoux, X. Chapaux, J. Canon, 2015, British Journal of Cancer.

Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus

R. Neuwirth, J. Canon, J. Diamond, 2019, Poster Discussion Abstracts.

1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

D. Miles, D. Cameron, J. Canon, 2015 .

J. Canon, M. Peeters, G. Pentheroudakis, 2018, British Journal of Cancer.

TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES

P. Neven, J. Machiels, J. Canon, 2009, Acta clinica Belgica.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

S. Iacobelli, T. Gorlia, F. Lévi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.